Chemoproteomic-enabled characterization of small GTPase Rab1a as a target of an N-arylbenzimidazole ligand's rescue of Parkinson's-associated cell toxicity-Reference-Cited by-同舟云学术

Chemoproteomic-enabled characterization of small GTPase Rab1a as a target of an N-arylbenzimidazole ligand's rescue of Parkinson's-associated cell toxicity

Published:2022 Issue:1 Volume:3 Page:96-111
ISSN:2633-0679
Container-title:RSC Chemical Biology
language:en
Short-container-title:RSC Chem. Biol.

Author:

Hatstat A. Katherine¹,Quan Baiyi¹,Bailey Morgan A.¹,Fitzgerald Michael C.¹,Reinhart Michaela C.¹,McCafferty Dewey G.¹^ORCID

Affiliation:

1. Department of Chemistry, Duke University, Durham, NC 27708, USA

Abstract

The development of phenotypic models of Parkinson's disease (PD) has enabled screening and identification of phenotypically active small molecules that restore complex biological pathways affected by PD toxicity.

Funder

National Institute of Neurological Disorders and Stroke

National Institute of General Medical Sciences

National Science Foundation

Michael J. Fox Foundation for Parkinson's Research

Publisher

Royal Society of Chemistry (RSC)

Subject

Biochemistry, Genetics and Molecular Biology (miscellaneous),Molecular Biology,Biochemistry,Chemistry (miscellaneous)

Link

http://pubs.rsc.org/en/content/articlepdf/2022/CB/D1CB00103E

Reference84 articles.